Annexon Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target classical complement-driven inflammation in diseases of the body, brain, and eye. The company’s current pipeline includes investigational medicines for autoimmune, neurodegenerative, neuroimmune, and ophthalmic conditions, with programs designed to block C1q, the initiating molecule of the classical complement pathway. Its product candidates are being studied across areas such as Guillain-Barré syndrome, geographic atrophy, and other serious inflammatory disorders. Annexon’s work centers on complement biology, a mechanism involved in immune activation and tissue damage, giving the company a distinct position within precision immunotherapy research. Headquartered in Brisbane, California, Annexon serves the biotechnology and drug development market through clinical research, translational science, and late-stage therapeutic development.
Website1400 Sierra Point Parkway
Brisbane, CA, 94005
United States
Annexon bets on functional outcomes in geographic atrophy & GBS; ARCHER II vision endpoints read out in Q4 2026. Click for more on ANNX stock.
BRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on September 12, 2026, in accordance with Nasdaq Listing Rule
BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences: Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9,
Investors talking about ANNX also mention
What share of all stock conversation is about ANNX?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% +0 | 0% +0 | 0% 0 | 0% +0 |
Of the messages about ANNX that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 100% | 92.31% | 75% -12.27 | 50% -33.01 | ||
| Bearish | 0% | 7.69% | 25% +12.27 | 50% +33.01 |
Of the messages about ANNX that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | 100% | 80.65% | 63.78% | ||
| Analysts | — | 0% | 19.35% | 24.61% | ||
| Technical Analysis | — | 0% | 0% | 11.24% | ||
| Earnings | — | 0% | 0% | 0.37% | ||
| Controversies | — | 0% | 0% | 0% | ||
| Macro | — | 0% | 0% | 0% |
Of the messages about ANNX, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 100% | 63.64% | 15.7% | 56.44% | ||
| Newcomers | 0% | 36.36% | 84.3% | 43.56% |